Antibody

Displaying 1 - 5 of 5


Targeted photodynamic therapy for S. aureus infections

Vanderbilt researchers have developed a combination photodynamic therapy (PDT) for targeting MRSA infections in skin that is not only effective but also HIGHLY SPECIFIC and LESS SUSCEPTIBLE TO RESISTANCE, adding a much needed therapy to our quickly depleting arsenal against this pathogen.


Licensing Contact

Cameron Sargent

615.322.5907

New Drug for Blood Clot: FXII Inhibitors to Treat Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, which may cause reduced blood flow to a tissue, or even tissue death. Thrombosis, inflammation, and infections are responsible for >70% of all human mortality. Thrombosis is also the major factor for heart disease and stroke. 500,000 die from thrombosis every year in Europe. Inhibitory treatment of these conditions may also improve the outcomes of several non-fatal diseases. Researchers from Vanderbilt University and Oregon Health & Science University have jointly discovered new monoclonal antibodies that potently inhibit the blood coagulation protein factor XII (FXII), a critical player in the pathway, and anticoagulate blood. This invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Antibody
Assays/Screening

Anti-human Myeloid Cell Nuclear Differentiation Monoclonal Antibody

The antibody is a rat IgG1 monoclonal, clone 3C1.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Antibody
Assays/Screening

Rabbit Anti-Fibroblast Specific Protein 1 Polyclonal Antibody

This research targets FSP1.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Eric Neilson
Research Tools
Antibody
Assays/Screening

Rabbit-Anti-mouse Pancreatic and Duodenal Homebox Gene-1 Antibody

This research targets Pdx-1.


Licensing Contact

Cameron Sargent

615.343.2430

Inventors

Christopher Wright